MISSION

PASSION CAN CURE ANYTHING!

WHY WE DO IT

The 2018 Nobel Prize in Medicine was awarded to two cancer immunotherapy researchers (J. Allison and T. Honjo), acknowledging the fact that checkpoint blockade immunotherapy is revolutionizing clinical oncology. However, only a subset of patients exhibit durable clinical responses and new technologies are needed to enable highly precise and effective immunotherapy in ALL cancer patients.

WHAT WE DO

We develop and apply next-generation mass spectrometry technologies to advance the field of cancer immunotherapy.

  • We aim to better understand the mechanisms of tumor response and resistance to checkpoint immunotherapy

 

  • We identify protein biomarkers of response and relapse to checkpoint immunotherapy

 

  • We identify new forms of tumor-specific neoantigens to design innovative cancer vaccines

 

  • We are co-founder of the Human Immuno-Peptidome Project (HIPP) and we develop the SysteMHC Atlas project to enable "Big Immuno-Peptidomic Data" research and management

HOW WE DO IT

  • We apply mass spectrometry-based proteomics, immunopeptidomics, computational mass spectrometry and bioinformatics approaches

 

  • We collaborate with researchers and clinical investigators 

 

  • We build the dream team! 

© 2019 by CARON LAB

Etienne Caron, PhD

PRINCIPAL INVESTIGATOR ASSISTANT PROFESSOR

email

Paul Drogaris, PhD

DIRECTOR OF MASS
SPECTROMETRY PLATFORM

 

email

Isabelle Sirois, PhD

RESEARCH ASSOCIATE
LAB MANGER

email

CARONLAB